Vitiligo is an acquired idiopathic depigmentary condition characterized by the appearance of depigmented patches on the skin and/ or mucous membrane. These patches may appear at various sites of the body, may be localized, segmental or generalized, of various colours e.g.

hypopigmented, milky white or pink. This may affect both sex and all age groups. Though it does not affect the general health but considered a social stigma which leads to sociopsychological problems. This study was designed and carried out to evaluate the efficacy and safety of Unani drug UNIM-046 in vitiligo cases in RRIUM, Aligarh.

Out of 25 patients studied, 7 patients showed 40% repigmentation, 12 patients 41 to 70% repigmentation, 3 patients 71 to 90 % repigmentation and 3 patients 91 to 100% repigmentation on different affected parts of the body. In biochemical studies a significant reduction on the levels of Serum Total Protein (P<0.01) and Serum Albumin (P<0.01) was found; however UNIM-046 significantly increased the levels of Serum Globulin (P<0.05); while decreasing the A/G ratio (P<0.001) during follow-up in Bars patients. UNIM-046 significantly increases the levels of Serum Glutamate Pyruvate Transaminase (SGPT) (P<0.01), While a reduction in the level of Serum Glutamate Oxaloacetate Transaminase (SGOT) P<0.01) was observed whereas a significant increases in the levels of Serum Alkaline Phosphatase enzyme, (within normal limits) (P<0.001) was observed when compared with pre-treatment values. In haematological studies, a significant decrease in the levels of Erythrocyte Sedimentation Rate (ESR) (P<0.01), Red Blood Corpuscles (RBC) count (P<0.01) and lymphocyte Count (P<0.01) was observed. However, significant increase was observed in Eosinophil Count (P<0.05). Thus, test Unani formulation is suggested to be effective as well as safe for Bars patients.